4.5 Review

Parkinson's Disease Dementia

Journal

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 10, Issue 4, Pages 292-298

Publisher

SPRINGER
DOI: 10.1007/s11910-010-0113-7

Keywords

Parkinson's disease; Dementia; Epidemiology; Pathology; Diagnosis; Treatment

Funding

  1. Teva-Lundbeck
  2. Orion
  3. Boehringer-Ingelheim
  4. GlaxoSmithKline
  5. Novartis
  6. Eisai
  7. UCB
  8. GE
  9. Michael J. Fox Foundation

Ask authors/readers for more resources

Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly slow and incomplete. To significantly affect PDD, novel disease-modifying agents, rather than more traditional neurotransmitter replacement approaches, likely will be required.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available